

Substitute Form PTO-1595

Attorney Docket Number: 50291/002001

## Certificate of Facsimile Transmission

Date of Transmission: May 4, 2006

I hereby certify that this correspondence is being transmitted by facsimile to Attention: Mail Stop Assignment Recordation Services, Director of the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 571-273-0140.

Guy Bendsley  
Printed Name of Person Sending Transmission

Guy Bendsley  
Signature of Person Sending Transmission

### RECORDATION FORM COVER SHEET PATENTS ONLY

Please record the attached document.

<p>1. Names of all conveying parties:</p> <p>NEUROCHEM (INTERNATIONAL) LIMITED NEUHAUSSTRASSE 5 6318 WALCHIL CANTON ZUG, SWITZERLAND</p> <p>Additional names attached: NO</p>	<p>2. Names and addresses of all receiving parties:</p> <p>NEUROCHEM (INTERNATIONAL) LIMITED PSE-C (PARC SCIENTIFIQUE) EPFL-ECUBLENS 1015 LAUSANNE SWITZERLAND</p> <p>Additional names/addresses attached: NO</p>
<p>3. Nature of conveyance:</p> <p><input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other: <u>Change of address</u></p> <p>Execution Date: December 21, 2004</p>	<p><b>Resubmission of Document ID 700256293A</b></p>
<p>4. Application numbers or patent numbers:</p> <p>A. Patent Application Number(s): 10/009,122</p>	<p>B. Patent Number(s):</p>
<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Susan M. Michaud, Ph.D., REG NO. 42,885 Clark &amp; Elbing LLP 101 Federal Street Boston, MA 02110 Customer No.: 21559</p>	<p>6. Total number of applications/patents involved: 1</p> <p>7. Total fee (37 C.F.R. § 3.41): \$40.00 <input type="checkbox"/> Fee enclosed <input checked="" type="checkbox"/> Authorized to charge deposit account</p> <p>8. Deposit account number: 03-2095. Please apply any additional charges, or any credits, to Deposit Account No. 03-2095.</p>

DO NOT USE THIS SPACE

9. Statement and signature: *To the best of my knowledge and belief, the foregoing information is true and correct and the attached is the original document or a true copy thereof.*

Susan M. Michaud, Ph.D.  
Name of person signing

Susan M. Michaud  
Signature

May 3, 2006  
Date

[Home](#) | [Site Map](#) | [Careers](#) | [Contact Us](#) | [Search](#) | [Version française](#)[News](#) [Financial](#) [Scientific](#) [Pipeline](#) [Commercial](#)  
[About Us](#) [Room Information](#) [Developments of products](#) [Opportunities](#)[Directions to the Head Office](#)


## Contact Us

Neurochem's Canadian head office and lab complex is situated in the Parc scientifique et de haute technologie de Laval, Quebec, Canada. This scientific centre is world-renown as a high-quality technological hub, housing the largest concentration of biopharmaceutical companies in Quebec.

Our offices are located north of the island of Montreal, in the city of Laval, just off highway 15 and within 40 minutes from downtown.

Neurochem Inc.  
275 Armand-Frappier Blvd.  
Laval, Québec,  
Canada H7V 4A7

Tel.: (450) 680-4500  
Fax: (450) 680-4501  
or: [webinfo@neurochem.com](mailto:webinfo@neurochem.com)



## Neurochem (International) Limited



PSE-C (Parc Scientifique)  
EPFL-Écublens  
1015 Lausanne  
Switzerland

Tel.: +41 (0)21 693 90 90  
Fax: +41 (0)21 693 90 91  
or: [chinfo@neurochem.com](mailto:chinfo@neurochem.com)

For more information about Neurochem's Investors Relations activities, please contact: [ir@neurochem.com](mailto:ir@neurochem.com)

For more information about Neurochem's clinical trials, please contact our Program Information Center.

To send us your resume: [careers@neurochem.com](mailto:careers@neurochem.com)

We value your opinion and we would like to receive your comments and suggestions on this website via: [webmaster@neurochem.com](mailto:webmaster@neurochem.com)

**PATENT**